Literature DB >> 24794163

Safe use of repetitive transcranial magnetic stimulation in patients with implanted vagus nerve stimulators.

Noah S Philip1, S Louisa Carpenter2, Linda L Carpenter3.   

Abstract

Vagus nerve stimulation (VNS) and repetitive transcranial stimulation (rTMS) devices are FDA cleared for therapeutic use in treatment resistant depression. Since VNS systems have ferromagnetic components and large-scale safety testing has not been done, the implanted VNS device is considered a contraindication for rTMS therapy. This contraindication should not be considered absolute, as VNS components typically lie outside the electromagnetic field generated by an rTMS treatment coil. We solicited information from clinicians at several academic medical centers through an informal survey about their use of rTMS for depressed patients with implanted VNS systems, and reviewed relevant safety issues with one rTMS device manufacturer. rTMS clinical practices may use special consent procedures and take additional precautions to enhance safety in these situations. Specific recommendations are provided for minimizing risks (heating or movement of VNS components and unintended change in VNS stimulation parameters) when delivering rTMS to patients with implanted VNS systems. Published by Elsevier Inc.

Entities:  

Keywords:  Repetitive transcranial magnetic stimulation; Safety; Treatment-resistant depression; Vagus nerve stimulation

Mesh:

Year:  2014        PMID: 24794163     DOI: 10.1016/j.brs.2014.04.001

Source DB:  PubMed          Journal:  Brain Stimul        ISSN: 1876-4754            Impact factor:   8.955


  3 in total

1.  Consensus Recommendations for the Clinical Application of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Depression.

Authors:  Shawn M McClintock; Irving M Reti; Linda L Carpenter; William M McDonald; Marc Dubin; Stephan F Taylor; Ian A Cook; John O'Reardon; Mustafa M Husain; Christopher Wall; Andrew D Krystal; Shirlene M Sampson; Oscar Morales; Brent G Nelson; Vassilios Latoussakis; Mark S George; Sarah H Lisanby
Journal:  J Clin Psychiatry       Date:  2018 Jan/Feb       Impact factor: 4.384

Review 2.  Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines.

Authors:  Simone Rossi; Andrea Antal; Sven Bestmann; Marom Bikson; Carmen Brewer; Jürgen Brockmöller; Linda L Carpenter; Massimo Cincotta; Robert Chen; Jeff D Daskalakis; Vincenzo Di Lazzaro; Michael D Fox; Mark S George; Donald Gilbert; Vasilios K Kimiskidis; Giacomo Koch; Risto J Ilmoniemi; Jean Pascal Lefaucheur; Letizia Leocani; Sarah H Lisanby; Carlo Miniussi; Frank Padberg; Alvaro Pascual-Leone; Walter Paulus; Angel V Peterchev; Angelo Quartarone; Alexander Rotenberg; John Rothwell; Paolo M Rossini; Emiliano Santarnecchi; Mouhsin M Shafi; Hartwig R Siebner; Yoshikatzu Ugawa; Eric M Wassermann; Abraham Zangen; Ulf Ziemann; Mark Hallett
Journal:  Clin Neurophysiol       Date:  2020-10-24       Impact factor: 4.861

3.  Synchronized cervical VNS with accelerated theta burst TMS for treatment resistant depression.

Authors:  Mark S George; Kevin A Caulfield; Kathleen O'Leary; Bashar W Badran; E Baron Short; Sarah M Huffman; Xingbao Li; Suzanne E Kerns; Nolan R Williams
Journal:  Brain Stimul       Date:  2020-08-07       Impact factor: 8.955

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.